Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Harrow Inc (NQ: HROW )

49.67 -1.32 (-2.59%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Harrow Inc

< Previous 1 2 3 4 Next >
Melt Pharmaceuticals Announces Exclusive Development and License Agreement with Catalent for Its Zydis® Fast-Dissolve Technology for Use in MELT-300 for Needle- and Opioid-Free Procedural Sedation
From Melt Pharmaceuticals, Inc.
Via Business Wire
Harrow Announces Second Quarter 2023 Financial Results
From Harrow Health, Inc.
Via Business Wire
Harrow Launches VIGAMOX® in the U.S.
From Harrow Health, Inc.
Via Business Wire
Harrow Health Inc. (NASDAQ: HROW) is a Stock Spotlight on 5/30
Via Investor Brand Network
Harrow Health Inc. (NASDAQ: HROW) is a Stock Spotlight on 5/9
Via Investor Brand Network
Harrow to Announce Second Quarter 2023 Financial Results on August 9, 2023
From Harrow Health, Inc.
Via Business Wire
Harrow Prices $60 Million Public Offering of Common Stock
From Harrow Health, Inc.
Via Business Wire
Harrow Acquires Santen’s Branded Ophthalmic Portfolio
From Harrow Health, Inc.
Via Business Wire
Harrow Health Inc. (NASDAQ: HROW) is a Stock Spotlight on 5/1
Via Investor Brand Network
Harrow Health Inc. (NASDAQ: HROW) is a Stock Spotlight on 4/21
Via Investor Brand Network
Harrow Health Inc. (NASDAQ: HROW) is a Stock Spotlight on 4/4
Via Investor Brand Network
Harrow Health Inc. (NASDAQ: HROW) Climbs to New 52-Week High
Via Investor Brand Network
Harrow Provides Select Preliminary Second Quarter 2023 Financial Guidance
From Harrow Health, Inc.
Via Business Wire
Harrow Announces Proposed Public Offering of Common Stock
From Harrow Health, Inc.
Via Business Wire
Harrow Acquires U.S. and Canadian Commercial Rights to VEVYE® (Cyclosporine Ophthalmic Solution) 0.1% from Novaliq
From Harrow Health, Inc.
Via Business Wire
Harrow to Participate in B. Riley Securities 23rd Annual Institutional Investor Conference on May 24, 2023
From Harrow
Via Business Wire
Harrow Health Inc. (NASDAQ: HROW) is a Stock Spotlight on 3/22
Via Investor Brand Network
NASDAQ:HROW Shareholder Notice: Investigation over Possible Breaches of Fiduciary Duties at Harrow Health, Inc
San Diego, CA -- (SBWIRE) -- 05/16/2023 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Harrow Health, Inc. 
Via SBWire
Harrow Announces First Quarter 2023 Financial Results
From Harrow Health, Inc.
Via Business Wire
Harrow to Launch FDA-Approved IHEEZO™ at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
From Harrow
Via Business Wire
Harrow Launches ILEVRO®, NEVANAC®, and MAXIDEX® in the U.S.
From Harrow
Via Business Wire
Harrow to Announce First Quarter 2023 Financial Results on May 11, 2023
From Harrow
Via Business Wire
Harrow Announces New $100 Million Secured Credit Facility with Oaktree
From Harrow
Via Business Wire
Harrow Announces Fourth Quarter and Year-End 2022 Financial Results
From Harrow
Via Business Wire
ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Harrow Health, Inc. Investors to Inquire About Securities Class Action Investigation - HROW, HROWL, HROWM
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Harrow Announces Transitional Pass-Through Reimbursement Status for IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3%
From Harrow
Via Business Wire
GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Harrow Health, Inc. Investors to Inquire About Securities Class Action Investigation - HROW, HROWL, HROWM
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Harrow Health, Inc. (NASDAQ:HROW) Shareholder Notice: Investigation over Possible Securities Laws Violations
San Diego, CA -- (SBWIRE) -- 03/08/2023 -- Harrow Health, Inc. is under investigation over potential securities laws in connection with certain financial statements. 
Via SBWire
Harrow Announces Appointment of Mark Mannebach, Ph.D., R.Ph. as Head of Regulatory Affairs and Pharmacovigilance
From Harrow
Via Business Wire
ROSEN, A LEADING LAW FIRM, Encourages Harrow Health, Inc. Investors with Losses to Inquire About Securities Class Action Investigation - HROW, HROWL, HROWM
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.